伏立康唑治疗恶性血液病患者侵袭性真菌感染的临床研究  

Clinical effect of voriconazole on treatment of invasive fungal infections in patients with hematological malignancies

作　　者：刘珍[1,2] 郑翠苹[1,2] 周文锦[1,2] 俞康[1,2] 

机构地区：[1]温州医科大学定理临床学院 [2]温州市中心医院血液内科,浙江温州325000

出　　处：《中华医院感染学杂志》2014年第13期3198-3200,共3页Chinese Journal of Nosocomiology

基　　金：浙江省卫生厅基金项目(ZW-2010B-1032)

摘　　要：目的探讨伏立康唑序贯治疗恶性血液病患者侵袭性真菌感染的临床效果,为临床治疗该病提供可借鉴的资料。方法选取2010年1月-2013年4月收治的恶性血液病合并侵袭性真菌感染患者186例,随机分为两组,其中对照组91例、观察组95例,对照组患者实施常规伏立康唑静脉治疗,观察组患者给予伏立康唑静脉序贯口服治疗,对两组患者症状改善、临床疗效以及不良反应进行评价;采用SPSS13.0软件进行分析。结果观察组患者临床治愈率及总有效率分别为25.26%、58.95%,对照组分别为25.27%、58.24%,两组患者临床治愈率和总有效率以及症状改善差异均无统计学意义;观察组患者不良反应发生率为4.21%,明显低于对照组的8.79%,两组比较差异有统计学意义(P<0.05)。结论通过静脉给药序贯口服给药的方法使用伏立康唑,对恶性血液病患者侵袭性真菌感染在保证治疗效果的同时,可降低患者的不良反应,是一种较为理想的给药方式。OBJECTIVE To explore the clinical effect of voriconazole on sequential treatment of invasive fungal in- fections in patients with hematological malignancies so as to provide guidance for the clinical treatment of the dis- ease. METHODS A total of 186 hematological malignancies patients complicated with invasive fungal infections who were treated in the hospital from Jan 2010 to Apt 2013 were enrolled in the study and randomly divided into two groups, then the 91 cases in the control group were treated with conventional intravenous administration of vori- conazole, while the 95 cases in the observation group were given the intravenous sequential oral administration of voriconazole, the improvement of symptoms, clinical efficacy, and adverse reactions were evaluated, and the sta- tistical analysis was performed with the use of SPSS13.0 software. RESULTS The clinical cure rate was 25.26 % in the observation group, 25.27% in the control group; the total effective rate was 58. 95% in the observation group, 58.24% in the control group, the difference in the clinical cure rate, the total effective rate, or improve- ment of symptoms between the two groups was not significant. The incidence of adverse reactions was 4.21% in the observation group, significantly lower than 8.79% in the control group, and the difference was statistically significant （P〈0.05）. CONCLUSION The intravenous sequential oral administration of voriconazole is an ideal ad- ministration approach for the hematological malignancies patients complicated with invasive fungal infections, and it can ensure the curative effect and reduce the incidence of adverse reactions.

关 键 词：伏立康唑 序贯治疗 恶性血液病 真菌 感染 

分 类 号：R978.1[医药卫生—药品]